TY - JOUR
T1 - Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury
AU - Massagli, Teresa L.
AU - Cardenas, Diana D.
PY - 1999/9
Y1 - 1999/9
N2 - Objective: To review the use of pamidronate to treat immobilization hypercalcemia after acute spinal cord injury (SCI) in 9 cases. Design: Retrospective case series. Setting: Two inpatient rehabilitation programs, one pediatric and one adult, in the Northwest Regional Spinal Cord Injury System. Patients: Patients with acute SCI who developed immobilization hypercalcemia that was treated with pamidronate. Results: Nine patients (7 men, 2 women), ages 15 to 41yrs, with SCI (8 tetraplegia, 1 paraplegia) were treated using pamidronate between 1994 and 1998. A single dose of 60mg of pamidronate resolved the hypercalcemia or its symptoms in 7 (78%) patients within days. One patient required a second dose (90mg) and one patient required three additional doses (the fourth at 90mg) to achieve resolution of the hypercalcemia or symptoms. Side effects were mild and included drug- related fever in one patient and transient asymptomatic hypocalcemia in four patients. Conclusion: Pamidronate was effective in treating immobilization hypercalcemia caused by SCI. Its advantages include its effectiveness, the duration of treatment, ease of administration, and elimination of the need for long-term intravenous saline or daily medications.
AB - Objective: To review the use of pamidronate to treat immobilization hypercalcemia after acute spinal cord injury (SCI) in 9 cases. Design: Retrospective case series. Setting: Two inpatient rehabilitation programs, one pediatric and one adult, in the Northwest Regional Spinal Cord Injury System. Patients: Patients with acute SCI who developed immobilization hypercalcemia that was treated with pamidronate. Results: Nine patients (7 men, 2 women), ages 15 to 41yrs, with SCI (8 tetraplegia, 1 paraplegia) were treated using pamidronate between 1994 and 1998. A single dose of 60mg of pamidronate resolved the hypercalcemia or its symptoms in 7 (78%) patients within days. One patient required a second dose (90mg) and one patient required three additional doses (the fourth at 90mg) to achieve resolution of the hypercalcemia or symptoms. Side effects were mild and included drug- related fever in one patient and transient asymptomatic hypocalcemia in four patients. Conclusion: Pamidronate was effective in treating immobilization hypercalcemia caused by SCI. Its advantages include its effectiveness, the duration of treatment, ease of administration, and elimination of the need for long-term intravenous saline or daily medications.
UR - http://www.scopus.com/inward/record.url?scp=0032822928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032822928&partnerID=8YFLogxK
U2 - 10.1016/S0003-9993(99)90050-3
DO - 10.1016/S0003-9993(99)90050-3
M3 - Article
C2 - 10488998
AN - SCOPUS:0032822928
VL - 80
SP - 998
EP - 1000
JO - Archives of Physical Medicine and Rehabilitation
JF - Archives of Physical Medicine and Rehabilitation
SN - 0003-9993
IS - 9
ER -